scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1037848838 |
P356 | DOI | 10.1186/1472-6963-8-196 |
P932 | PMC publication ID | 2562379 |
P698 | PubMed publication ID | 18816393 |
P5875 | ResearchGate publication ID | 23282111 |
P2093 | author name string | Susan E Tett | |
Nadia Barozzi | |||
P2860 | cites work | Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach | Q24673561 |
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study | Q24803974 | ||
Underutilization of preventive strategies in patients receiving NSAIDs | Q28165863 | ||
Nonsteroidal anti-inflammatory drug prescribing: past, present, and future | Q28175506 | ||
Understanding NSAIDs: from aspirin to COX-2 | Q28186635 | ||
Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature | Q28200737 | ||
Auditing prescription practice using explicit criteria and computerized drug benefit claims data | Q32129240 | ||
The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature | Q34034067 | ||
Maximizing the benefit--minimizing the risk: the developing role of radiographers in performing intravenous injections | Q34340658 | ||
Personal formularies. An index of prescribing quality? | Q34363667 | ||
Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study | Q34444119 | ||
Gastrointestinal effects of NSAIDs and coxibs | Q35072859 | ||
Key questions concerning paracetamol and NSAIDs for osteoarthritis. | Q35551913 | ||
The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland | Q35827761 | ||
Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk | Q36464651 | ||
Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals | Q36636548 | ||
Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors | Q39711512 | ||
Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors | Q39721735 | ||
Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia. | Q40418551 | ||
Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland | Q40518784 | ||
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. | Q44617592 | ||
Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. | Q50724553 | ||
Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs | Q67903664 | ||
Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee | Q71094719 | ||
Recent changes in the profile of prescription NSAID use in Australia | Q73692458 | ||
Drug utilization 90%--a simple method for assessing the quality of drug prescribing | Q74648667 | ||
What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? | Q80629745 | ||
P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Australia | Q408 |
paracetamol | Q57055 | ||
P304 | page(s) | 196 | |
P577 | publication date | 2008-09-24 | |
P1433 | published in | BMC Health Services Research | Q4835946 |
P1476 | title | Non-steroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors and paracetamol use in Queensland and in the whole of Australia | |
P478 | volume | 8 |
Q35834675 | Actions following adverse drug events - how do these influence uptake and utilisation of newer and/or similar medications? |
Q33953093 | Cause for concern in the use of non-steroidal anti-inflammatory medications in the community--a population-based study |
Q45219814 | The increasing rates of acute interstitial nephritis in Australia: a single centre case series. |
Q43219102 | Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information |
Search more.